

1 **TITLE**

2 Fully automated histological classification of cell types and tissue regions of celiac disease is  
3 feasible and correlates with the Marsh score

4

5 **AUTHORS**

6 Michael GRIFFIN<sup>1</sup>, M.S., [michael.griffin@pathai.com](mailto:michael.griffin@pathai.com)

7 Aaron M. GRUVER<sup>2</sup>, M.D., Ph.D., [gruver\\_aaron\\_m@lilly.com](mailto:gruver_aaron_m@lilly.com)

8 Chintan SHAH<sup>1</sup>, M.S., [chintan.shah@pathai.com](mailto:chintan.shah@pathai.com)

9 Qasim WANI<sup>1</sup>, B.S., [qasim.wani@pathai.com](mailto:qasim.wani@pathai.com)

10 Darren FAHY<sup>1</sup>, B.S., [darren.fahy@pathai.com](mailto:darren.fahy@pathai.com)

11 Archit KHOSLA<sup>1</sup>, M.S., [archit.khosla@pathai.com](mailto:archit.khosla@pathai.com)

12 Christian KIRKUP<sup>1</sup>, M.S., [christian.kirkup@pathai.com](mailto:christian.kirkup@pathai.com)

13 Daniel BORDERS<sup>1</sup>, M.S., [daniel.borders@pathai.com](mailto:daniel.borders@pathai.com)

14 Jacqueline A. BROSNAN-CASHMAN<sup>1</sup>, Ph.D., [jackie.brosnancashman@pathai.com](mailto:jackie.brosnancashman@pathai.com)

15 Angie D. FULFORD<sup>2</sup>, M.S., [fulford\\_angie\\_d@lilly.com](mailto:fulford_angie_d@lilly.com)

16 Kelly M. CREDILLE<sup>2</sup>, D.V.M, Ph.D., [credille\\_kelly\\_m@lilly.com](mailto:credille_kelly_m@lilly.com)

17 Christina JAYSON<sup>1</sup>, Ph.D., [christina.jayson@pathai.com](mailto:christina.jayson@pathai.com)

18 Fedaa NAJDAWI<sup>1,\*</sup>, M.D., [fedaa.najdawi@pathai.com](mailto:fedaa.najdawi@pathai.com)

19 Klaus GOTTLIEB<sup>2,\*</sup>, M.D., Ph.D., [klaus.gottlieb@lilly.com](mailto:klaus.gottlieb@lilly.com)

20 \* Fedaa Najdawi and Klaus Gottlieb contributed equally as co-senior authors

21

22 **AUTHORS' AFFILIATIONS**

23 <sup>1</sup> PathAI, Boston, MA, USA

24 <sup>2</sup> Eli Lilly and Company, Indianapolis, IN, USA

25

26

27 **AUTHOR FOR CORRESPONDENCE**

28 Fedaa Najdawi

29 PathAI, Inc.

30 1325 Boylston Street, Suite 10000

31 Boston, MA 02215

32 USA

33 Tel: +1-617-500-8457

34 Email: [fedaa.najdawi@pathai.com](mailto:fedaa.najdawi@pathai.com)

35

36

37

38

39

40

41

42

43

44

45

46

47

48 **ABSTRACT**

49 **Aims** Histological assessment is essential for the diagnosis and management of celiac  
50 disease. Current scoring systems, including modified Marsh (Marsh–Oberhuber) score, lack  
51 inter-pathologist agreement. To address this unmet need, we aimed to develop a fully  
52 automated, quantitative approach for histology characterisation of celiac disease.

53 **Methods** Convolutional neural network models were trained using pathologist  
54 annotations of haematoxylin and eosin-stained biopsies of celiac disease mucosa and  
55 normal duodenum to identify cells, tissue and artifact regions. Human interpretable features  
56 were extracted and the strength of their correlation with Marsh scores were calculated using  
57 Spearman rank correlations.

58 **Results** Our model accurately identified cells, tissue regions and artifacts, including  
59 distinguishing intraepithelial lymphocytes and differentiating villous epithelium from crypt  
60 epithelium. Proportional area measurements representing villous atrophy negatively  
61 correlated with Marsh scores ( $r=-0.79$ ), while measurements indicative of crypt hyperplasia  
62 and intraepithelial lymphocytosis positively correlated ( $r=0.71$  and  $r=0.44$ , respectively).  
63 Furthermore, features distinguishing celiac disease from normal colon were identified.

64 **Conclusions** Our novel model provides an explainable and fully automated approach for  
65 histology characterisation of celiac disease that correlates with modified Marsh scores,  
66 facilitating diagnosis, prognosis, clinical trials and treatment response monitoring.

67 **KEYWORDS**

68 MeSH terms:

- 69 • Artificial intelligence
- 70 • Celiac disease
- 71 • Histology
- 72 • Machine learning

73

## 74 **KEY MESSAGES**

75 What is already known on this topic

76 ➤ Prior research has utilised machine learning (ML) techniques to detect celiac disease  
77 and evaluate disease severity based on Marsh scores.

78 ➤ However, existing approaches lack the capability to provide fully explainable tissue  
79 segmentation and cell classifications across whole slide images in celiac disease  
80 histology.

81 ➤ The need for a more comprehensive and interpretable ML-based method for celiac  
82 disease diagnosis and characterisation is evident from the limitations of currently  
83 available scoring systems as well as inter-pathologist variability.

84 What this study adds

85 ➤ This study is the first to introduce an explainable ML-based approach that provides  
86 comprehensive, objective celiac disease histology characterisation, overcoming inter-  
87 observer variability and offering a scalable tool for assessing disease severity and  
88 monitoring treatment response.

89 How this study might affect research, practice or policy

90 ➤ This study's fully automated and ML-based histological analysis, including the  
91 correlation of Marsh scores, has the potential to enable more precise disease severity  
92 measurement, risk assessment and clinical trial endpoint evaluation, ultimately  
93 improving patient care.



## 94 INTRODUCTION

95 Celiac disease, an autoimmune disease triggered by dietary gluten, affects around 1% of the  
96 population.<sup>1</sup> Its diagnosis can be challenging due to symptom diversity, spanning from no  
97 symptoms to severe malabsorption.<sup>1 2</sup> Patients with celiac disease face a slightly increased  
98 overall risk of developing bowel lymphoma in comparison to the general population.<sup>2</sup>

99 Histological assessment is crucial for the diagnosis and management of celiac  
100 disease,<sup>3</sup> as well as for endpoint assessment in clinical trials,<sup>4</sup> with findings of intraepithelial  
101 lymphocytosis, crypt hyperplasia and villous atrophy indicative of the presence of the  
102 disease.<sup>5</sup> Clinical study endpoints often rely on a quantification of disease activity,  
103 demonstrated by changes in histology and characterised according to disease severity by  
104 classification systems such as the modified Marsh (Marsh–Oberhuber) score.<sup>3 6</sup> However,  
105 inter-observer agreement is low for these metrics.<sup>6</sup> The United States Food and Drug  
106 Administration recommends using a clinically accepted histological scale such as the Marsh  
107 score for screening samples in clinical studies of treatments for celiac disease, to ensure  
108 patient eligibility at enrolment. Furthermore, histology is also recommended as a co-primary  
109 endpoint in these studies.<sup>7</sup>

110 Celiac disease is often underdiagnosed due to variation between pathologists in their  
111 assessment of biopsy tissue samples,<sup>8</sup> even if multiple biopsies are obtained.<sup>3 5</sup> Poor quality  
112 of biopsy tissue and overlapping histopathology features between related conditions may  
113 contribute to this variability.<sup>5 8 9</sup> Recently, there has been increased interest in applying  
114 machine learning (ML) to pathology,<sup>10 11</sup> including to improve the accuracy and efficiency of  
115 celiac disease diagnosis.<sup>12</sup>

116 Such automation is expected to significantly reduce variability,<sup>12 13</sup> enabling smaller  
117 clinical studies to attain sufficient statistical power to demonstrate treatment effects. Indeed,  
118 convolutional neural network (CNN) tissue and cell model predictions from gastrointestinal  
119 samples have been used to create human interpretable features (HIFs) that enable the

120 quantitative assessment of inflammatory pathological changes in non-celiac gastrointestinal  
121 diseases.<sup>16</sup>

122 While previous research has successfully employed ML to detect celiac disease and  
123 assess disease severity based on Marsh scores,<sup>13</sup> this study aims to bridge critical gaps in  
124 the current research landscape. The work presented here represents the first report of an ML  
125 application for celiac disease that provides fully explainable tissue segmentation and cell  
126 classifications across whole slide images (WSIs) of duodenal mucosal biopsies. Through this  
127 approach, we have enabled the extraction of HIFs, such as cell densities, cell count  
128 proportions, and tissue area proportions, all of which exhibit correlations with Marsh scores.  
129 By utilising ML-based quantification, this study aims to objectively and exhaustively  
130 characterise celiac disease histology, address the limitations of manual histological  
131 assessments, and provide granular data for translational research and clinical trials. We  
132 believe such an approach has tremendous potential as a scalable tool for measuring disease  
133 severity and monitoring treatment response.

134

## 135 **MATERIALS AND METHODS**

### 136 **Data set characteristics**

137 WSIs of haematoxylin and eosin (H&E)-stained biopsies of duodenal mucosa of varying  
138 celiac disease severity (N=318) and mucosa of normal duodenum (N=58) were collected  
139 from PathAI Diagnostics (Memphis, USA) (**supplemental figure 1**).

140 The cohort size was determined based on the project's scope and the availability of  
141 small intestine biopsies encompassing the full spectrum of celiac disease histology at the  
142 central laboratory. Slides were scanned at 40x objective magnification using the Aperio  
143 GT450 slide scanner (Leica Biosystems, Wetzlar, Germany). Celiac disease slides were split  
144 into training (n=230; 72.3%), validation (n=60; 18.9%) and test (n=28; 8.8%) datasets to  
145 ensure the even distribution of available patient metadata. For normal duodenum, slides  
146 were divided into a similar ratio of training (n=40; 69.0%), validation (n=12; 20.7%) and test  
147 (n=6; 10.3%) datasets.

### 148 **Machine learning-based tissue model development**

149 We developed a model to identify and quantify relevant tissue regions, and we also utilised a  
150 previously trained model to identify and quantify cell types and artifact regions<sup>16</sup> on H&E-  
151 stained WSIs of celiac disease and normal duodenum (**figure 1**). Using these identified cells  
152 and tissue regions, histological features relevant to celiac disease and representing  
153 surrogate measures of modified Marsh score components were quantified, including the  
154 proportion of intraepithelial lymphocytes to enterocytes in villous epithelium and the surface  
155 areas of villous epithelium and crypt epithelium. The latter two features assess villous height  
156 and crypt hyperplasia respectively.

157 WSIs were annotated by board-certified gastrointestinal pathologists. In total, 8356  
158 tissue region annotations were collected. Annotations of crypt epithelium, villous epithelium,  
159 crypt lumen, lamina propria, blood vessels, muscularis mucosa and other tissue (including  
160 Brunner's glands and submucosa) were used to train a HIF-based tissue segmentation

161 region model. From these annotations, a CNN model was trained to produce pixel-level  
162 predictions of small intestinal mucosa tissue regions. Previously developed models to detect  
163 and exclude tissue artifacts and identify and classify the cells in colon tissue were also  
164 deployed.<sup>16</sup> Tissue and cell model predictions were visualised as heatmaps on WSIs.  
165 Heatmap transformations were used to remove artifact regions (e.g. debris, tissue folds, out-  
166 of-focus regions), extracting features only from high-quality tissue.

### 167 **Validation and review of cell and tissue models**

168 A PathAI pathologist (F.N.) performed quality control of the tissue labels used for model  
169 training and qualitatively reviewed the tissue and cell overlays representing model  
170 predictions on H&E-stained WSIs. This qualitative review helped guide the iterative model  
171 development (**supplemental figure 2**).

172 To establish ground truth for cell model prediction accuracy, representative image  
173 frames were sampled (75  $\mu\text{m}$   $\times$  75  $\mu\text{m}$ ; N=160). Frames were exhaustively annotated for all  
174 model-predicted cell types by five gastrointestinal pathologists. Hierarchical clustering was  
175 performed on these annotations and model predictions as previously described to identify  
176 cell locations.<sup>16</sup> To account for potential pathologist bias and variability, Bayesian-estimated  
177 ground truths were used to quantify and compare the performance of the annotators and the  
178 model (**supplemental figure 3**).

### 179 **Evaluation of model-derived HIFs**

180 HIFs (e.g. the proportional area of villous epithelium relative to lamina propria) were  
181 extracted from WSIs of normal duodenum (N=52) and scored celiac disease (N=118). HIFs  
182 were correlated with modified Marsh scores (type 0, normal lesions; type 1, infiltrative  
183 lesions; type 2, hyperplastic lesions; and types 3a, 3b and 3c, destructive lesions)<sup>6</sup> using  
184 Spearman rank correlations. Scores only assessed the presence of >30 intraepithelial  
185 lymphocyte cells when differentiating scores 0 from 1 rather than quantifying any further  
186 increase in intraepithelial lymphocyte cells with increasing disease severity.

187           After establishing correlations between HIFs and modified Marsh scores, potential  
188 differences in the model-derived features between celiac disease and normal duodenum  
189 were evaluated.

## 190 **Statistical analysis**

191 To assess cell model performance, the harmonised average of precision and sensitivity (F1  
192 score) was calculated for both the cell model predictions and each pathologist annotation  
193 compared to the consensus on representative image frames. To evaluate the model-  
194 generated HIFs, each HIF was assessed for correlation with consensus modified Marsh  
195 scores using Spearman rank correlations. Data analyses in this study used the programming  
196 language Python (OpenEDG Python Institute, West Pomerania, Poland) for tissue and cell  
197 model development. Additionally, OpenSlide Python (Carnegie Mellon University, Pittsburgh,  
198 PA, USA) was used to load WSIs, Matplotlib (John D Hunter, Matplotlib Development Team  
199 and NumFOCUS, Austin, TX, USA) was used for plotting graphs, and PyTorch (PyTorch  
200 Foundation, the Linux Foundation, San Francisco, CA, USA) was used for tissue and cell  
201 model development.

202           To associate model-derived features of celiac disease following correlations with  
203 modified Marsh scores, mean (standard deviation) feature levels were used to show  
204 differences between celiac disease and normal duodenum. P values were calculated by  
205 independent *t*-test.

## 206 RESULTS

### 207 Model development for quantitation of celiac disease histological features

208 The tissue model developed, as well as the previously trained cell and artifact models,<sup>16</sup> were  
209 deployed on H&E-stained WSIs of celiac disease and normal duodenum. Relevant cell types  
210 identified included neutrophils, plasma cells, enterocytes, intraepithelial lymphocytes, non-  
211 intraepithelial lymphocytes, eosinophils and goblet cells (**figure 2**); all other cell types are  
212 predicted as “other cells”. In addition, tissue regions identified included villous epithelium,  
213 crypt epithelium, lamina propria, muscularis mucosa and blood vessels (**figure 3**). Tissue  
214 regions such as total epithelium and mucosa could also be extracted from the tissue  
215 segmentation overlays. The tissue model distinguished villous epithelium from crypt  
216 epithelium.

217 The cell model’s performance was validated by comparing it with pathologists’  
218 annotations using Bayesian-estimated ground truths. Here, we sought to concentrate this  
219 validation on overlapping cells, focusing on cell confusion. The cell model demonstrated  
220 acceptable sensitivity for most cell types (**figure 4**).

221 Cell model predictions were compared with labels from five gastrointestinal  
222 pathologists on representative image frames to determine model accuracy. We reported  
223 elements of the F1 score for both cell model predictions and pathologists’ labels for each of  
224 the cell types (**figure 5A,B**). Overall, cell model specificity remained relatively consistent and  
225 was similar to that of the pathologists for most cell types, with a slight difference being seen  
226 for plasma cells, while sensitivity was more variable outside the intraepithelial lymphocyte  
227 class.

### 228 Correlation of surrogate features with modified Marsh score

229 HIFs from our models were analysed to assess correlation with modified Marsh scores. The  
230 area of villous epithelium relative to mucosa was negatively correlated with modified Marsh  
231 score (Spearman  $r=-0.79$ ,  $p<0.0001$ ) (**figure 6A**). The area of crypt epithelium in tissue

232 (figure 6B) positively correlated with modified Marsh score (Spearman  $r=0.71$ ,  $p<0.0001$ ), as  
233 did the number of intraepithelial lymphocyte cells relative to enterocyte cells in villous  
234 epithelium (figure 6C) (Spearman  $r=0.44$ ,  $p<0.0001$ ). These results are summarised in  
235 **supplemental table 1**.

236 The HIFs extracted from the cell and tissue models distinguished normal biopsies from  
237 those with celiac disease. For example, the proportional area of villous epithelium relative to  
238 mucosa and the proportional area of villous epithelium relative to crypt epithelium were both  
239 lower in celiac disease tissue compared with normal tissue, while the proportional area of  
240 crypt epithelium relative to total epithelium, the proportional area of lamina propria over  
241 mucosa and the density of intraepithelial lymphocytes in villous epithelium were higher in  
242 celiac disease ( $p<0.0001$  for all comparisons) (table 1).

243 **Table 1** Association of model-derived features with celiac disease

	Feature	Normal duodenum	Celiac disease	P value
		Mean (SD)	Mean (SD)	
Features quantifying villous atrophy	Area proportion of villous epithelium over mucosa in tissue	0.33 (0.08)	0.15 (0.07)	<0.0001
	Area proportion of villous epithelium over all epithelium in tissue	0.58 (0.10)	0.36 (0.14)	<0.0001
	Area proportion of villous epithelium over lamina propria in tissue	1.11 (0.35)	0.36 (0.23)	<0.0001
Features quantifying crypt hyperplasia	Area proportion of crypt epithelium over usable tissue	0.21 (0.05)	0.23 (0.07)	0.12
	Area proportion of lamina propria over crypt epithelium in tissue	1.38 (0.49)	1.90 (0.82)	<0.0001
	Area proportion of crypt epithelium over all epithelium in tissue	0.42 (0.10)	0.64 (0.14)	<0.0001
	Area proportion of crypt epithelium over mucosa in tissue	0.24 (0.05)	0.27 (0.07)	<0.01
Surrogate features for villous height/ crypt depth ratio	Area proportion of villous epithelium over crypt epithelium in tissue	1.54 (0.87)	0.64 (0.47)	<0.0001
Features quantifying intraepithelial lymphocyte infiltration	Count proportion of intraepithelial lymphocytes over enterocytes in villous epithelium	0.20 (0.07)	0.31 (0.11)	<0.0001
	Density of intraepithelial lymphocytes in villous epithelium	910.27 (303.15)	1446.27 (463.91)	<0.0001
Features quantifying expansion of inflammatory cells in lamina propria	Count proportion of plasma cells over all cells in lamina propria	0.23 (0.05)	0.29 (0.10)	<0.001
	Density of plasma cells in lamina propria	2131.66 (593.54)	2725.74 (1171.97)	<0.001
	Density of lymphocytes in lamina propria	2483.02 (793.40)	1808.05 (641.31)	<0.0001
	Count proportion of lymphocytes over all cells in lamina propria	0.27 (0.06)	0.19 (0.06)	<0.0001



	Area proportion of lamina propria over mucosa in tissue	0.31 (0.04)	0.47 (0.08)	<0.0001
	Total number of cells in lamina propria	54,013.02 (28142.69)	89,593.13 (50,629.86)	<0.0001
Other features quantifying inflammatory cells	Count proportion of neutrophils over all cells in mucosa	0.03 (0.01)	0.05 (0.02)	<0.0001
	Count proportion of eosinophils over all cells in mucosa	0.02 (0.01)	0.03 (0.01)	<0.0001

244 SD, standard deviation.

## 245 **DISCUSSION**

246 Histological assessment of celiac disease plays a crucial role in diagnosing disease and  
247 evaluating the effectiveness of clinical interventions.<sup>3</sup> However, inter-observer variability can  
248 affect the consistency and accuracy of results.<sup>6</sup> To overcome this limitation and augment  
249 pathologists' assessments of disease severity, we aimed to develop a fully automated and  
250 explainable approach to quantify the cellular and tissue-based features of celiac disease in  
251 H&E-stained clinical samples. The HIFs extracted from this model reflected histological  
252 changes that were measured by modified Marsh scores, potentially providing a quantitative  
253 and reproducible means to assess celiac disease severity.

254 Our model produced continuous feature measurements that can be interpreted as  
255 surrogate markers of celiac disease pathology (**supplemental table 1**). The relationship of  
256 these features with the ordinal Marsh score categories can be used as a benchmark to  
257 measure the model's performance. For example, we examined the area of villous epithelium  
258 relative to the area of mucosa as an indicator of villous blunting, a hallmark of celiac disease,  
259 and found a negative correlation with higher modified Marsh scores. To gauge crypt  
260 hyperplasia, a more subtle feature, we examined the area of crypt epithelium relative to total  
261 epithelial area, revealing a positive correlation between this feature and Marsh scores at a  
262 Marsh score of 2 and above. The trained cell model directly quantitated the proportion of  
263 intraepithelial lymphocytes relative to the number of enterocytes within the villous structures.  
264 As expected, these values increased with disease severity.

265 Existing celiac disease scoring systems, such as the modified Marsh score, primarily  
266 rely on qualitative and descriptive categorisations, leading to subjectivity and limited  
267 sensitivity to subtle changes.<sup>17</sup> In this study, we propose an alternative approach, utilising ML  
268 techniques to enable continuous, quantitative evaluation of the histological changes in celiac  
269 disease. By capturing histological alterations on a granular and objective scale, this novel  
270 approach offers enhanced sensitivity to changes in intraepithelial lymphocyte density, as well

271 as villous and crypt epithelial surface area, overcoming limitations of the qualitative  
272 assessments of conventional manual scoring systems.

273         Some of our model-extracted HIFs directly quantified features of intraepithelial  
274 lymphocytes. This cell type is an essential consideration during disease assessment, as the  
275 presence of >30 intraepithelial lymphocytes per 100 enterocytes in the duodenum is a  
276 defining feature of celiac disease.<sup>18</sup> The HIFs extracted from our model include count  
277 proportions and/or density of intraepithelial lymphocytes, specifically in the villous epithelium.  
278 This model also allowed for the extraction of features relating to intraepithelial lymphocytes in  
279 crypt epithelium and a comparison of their density in villous and crypt epithelium, providing a  
280 comprehensive overview of the spatial distribution of this cell type within distinct epithelial  
281 regions. Additional relevant features included the proportional area of villous epithelium  
282 (quantifying the change related to villous atrophy), the proportional area of crypt epithelium  
283 (quantifying crypt hyperplasia) and the ratio of villous epithelium area to crypt epithelium area  
284 (quantitatively capturing the relationship of villous height to crypt depth).<sup>19</sup>

285         The key strengths of this study become apparent when considering that these model-  
286 generated features not only bear relevance to the modified Marsh scoring system but are  
287 also essential components of the histological hallmarks of celiac disease (**table 1**).<sup>19</sup> These  
288 HIFs encompass features not previously incorporated into any formalised scoring system,  
289 such as relative numbers and density of inflammatory cells (including lymphocytes, plasma  
290 cells, eosinophils and neutrophils) in lamina propria or in mucosa. These metrics  
291 characterise the immune micro-environment within celiac biopsies, as well as the total area  
292 and area proportion of lamina propria, capturing the expansion of lamina propria, a  
293 phenomenon known to be associated with disease activity.<sup>19</sup>

294         Furthermore, one of the key strengths of this study lies in our model's capacity to  
295 discern between normal duodenum and celiac disease through the quantification of features  
296 associated with the disease microenvironment in mucosal biopsies. As expected, quantifying  
297 features of villous atrophy, as evidenced by reduced area proportion of this feature, and the

298 augmented area proportion signifying mucosa crypt hyperplasia, distinguished between the  
299 histology of unaffected biopsies and those indicative of celiac disease. Supplementary  
300 quantitative attributes of the inflammatory microenvironment known to be associated with  
301 celiac disease, encompassing the infiltration of chronic inflammatory cells like lymphocytes  
302 and plasma cells within the lamina propria, coupled with the associated expansion of this  
303 layer,<sup>19</sup> further distinguished normal biopsy samples from those with celiac disease.  
304 Discernible differences between the two groups were also observed in the quantitative  
305 evaluation of granulocytes, which has been previously described.<sup>20 21</sup>

306         While our model was limited by the small sample size, additional assessment involving  
307 larger cohorts will allow future refinement of the model's performance. The cell model can  
308 also be trained specifically on duodenum biopsies and expanded to predict features  
309 associated with additional cell types (e.g. Paneth cells). An additional limitation of the current  
310 approach is related to the extraction of HIFs across a specific tissue area in the entire slide,  
311 which overlooks the potential variation between different tissue fragments. In a manual  
312 assessment of celiac disease in biopsies, pathologists often determine disease severity  
313 based on the most severely affected tissue region. To address this limitation, future work will  
314 focus on reporting HIFs separately for specific regions of interest within the tissue sample.  
315 This strategy is expected to allow for a more comprehensive and accurate assessment of  
316 disease severity within distinct tissue regions.

317         We foresee that ML-supported histological analysis will play a pivotal role in the  
318 advancement of precision medicine for patients with celiac disease. To our knowledge, this is  
319 the first report of fully explainable ML-based tissue and cell classifications across the WSIs of  
320 mucosal biopsies in celiac disease, enabling the extraction and statistical analysis of HIFs to  
321 empower translational research and clinical trials. The resulting quantitative model-generated  
322 HIFs can be used to build predictive models of existing Marsh scores or function as a  
323 continuous measurement, tracking histological change in celiac biopsies. Expanding upon  
324 this foundation, as we proceed to develop classification models aimed at predicting clinical

325 outcomes alongside slide-level scores, we anticipate that the interpretability enabled by the  
326 utilisation of HIFs is poised to serve a dual purpose: validating the integrity of these models  
327 and revealing novel insights into disease biology. We believe that this ML-based assessment  
328 has tremendous potential as a scalable tool for measuring disease severity, risk stratification,  
329 prognostic evaluation, evaluating endpoints in clinical trials and monitoring of treatment  
330 responses; ultimately, advancing the care of patients with celiac disease.

### 331 **Acknowledgements**

332 The authors would like to thank all study participants. The authors are grateful to the  
333 software engineering and machine learning teams at PathAI for developing the systems and  
334 pipelines used for model development and feature extraction.

### 335 **Contributors**

336 MG: conceptualisation, data curation, formal analysis, investigation, methodology, project  
337 administration, supervision, validation and visualisation, AMG: funding acquisition and writing  
338 (review and editing), CS: conceptualisation, data curation, formal analysis, investigation,  
339 methodology, validation and visualisation, QW: conceptualisation, data curation, formal  
340 analysis, investigation, methodology, validation and visualisation, DF: data curation, AK:  
341 conceptualisation, investigation, methodology, software and writing (review and editing), CK:  
342 conceptualisation, data curation and writing (review and editing), DB: conceptualisation,  
343 investigation, formal analysis and writing (review and editing), JABC: writing (original draft)  
344 and writing (review and editing), CJ: conceptualisation, data curation, formal analysis,  
345 investigation, methodology, project administration, validation and visualisation, FN:  
346 conceptualisation, data curation, formal analysis, investigation, methodology, project  
347 administration, validation, visualisation, writing (original draft) and writing (review and  
348 editing), KG: conceptualisation, funding acquisition, supervision and writing (review and  
349 editing). All authors: final approval of the manuscript. FN and KG are joint last authors.

### 350 **Funding support**

351 This study was sponsored by Eli Lilly and Company. Medical writing assistance was provided  
352 by Jason Vuong, BPharm, and Clare Weston, MSc, of ProScribe – Envision Pharma Group,  
353 and was funded by Eli Lilly and Company. ProScribe's services complied with international  
354 guidelines for Good Publication Practice.

### 355 **Role of the sponsor**

356 Eli Lilly and Company was involved in the study design, oversight and preparation of the  
357 manuscript.

358 **Competing interests**

359 AMG, ADF, KMC and KG are employees and shareholders of Eli Lilly and Company.

360 MG, CS, QS, DF, AK, CK, DB, JABC, CJ and FN are employees of PathAI.

361 **Patient consent for publication**

362 Not required.

363 **Ethics approval**

364 WCG IRB protocol number: 1316112

365 **Data availability statement**

366 Model parameters for cell and tissue models, and codes for model training, inference and  
367 feature extractions are not disclosed. Access requests for such code will not be considered  
368 to safeguard PathAI's intellectual property. All feature tables, as well as source code, for  
369 reproducing correlational analyses will be deposited to GitHub prior to publication, and the  
370 link will be provided at that time. Access to cell- and tissue-type heatmaps, as well as usage  
371 of cell- and tissue-type classification models, are available on reasonable request to  
372 academic investigators, without relevant conflicts of interest, for non-commercial use who  
373 agree not to distribute the data. Access requests can be made to: [publications@pathai.com](mailto:publications@pathai.com).

## REFERENCES

- 1 Lebwohl B, Sanders DS, Green PHR. Coeliac disease. *Lancet* 2018;391:70–81.
- 2 Marafini I, Monteleone G, Stolfi C. Association between celiac disease and cancer. *Int J Mol Sci* 2020;21:4155.
- 3 Rubio-Tapia A, Hill ID, Kelly CP, *et al.* ACG clinical guidelines: diagnosis and management of celiac disease. *Am J Gastroenterol* 2013;108:656–76.
- 4 Gottlieb K, Dawson J, Hussain F, *et al.* Development of drugs for celiac disease: review of endpoints for phase 2 and 3 trials. *Gastroenterol Rep (Oxf)* 2015;3:91–102.
- 5 Green PH, Cellier C. Celiac disease. *N Engl J Med* 2007;357:1731–43.
- 6 Corazza GR, Villanacci V, Zambelli C, *et al.* Comparison of the interobserver reproducibility with different histologic criteria used in celiac disease. *Clin Gastroenterol Hepatol* 2007;5:838–43.
- 7 US Food & Drug Administration (FDA). Celiac disease: developing drugs for adjunctive treatment to a gluten-free diet. 2022. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ceeliac-disease-developing-drugs-adjunctive-treatment-gluten-free-diet> (accessed May 2023).
- 8 Mubarak A, Nikkels P, Houwen R, *et al.* Reproducibility of the histological diagnosis of celiac disease. *Scand J Gastroenterol* 2011;46:1065–73.
- 9 Syed S, Ehsan L, Shrivastava A, *et al.* Artificial intelligence-based analytics for diagnosis of small bowel enteropathies and black box feature detection. *J Pediatr Gastroenterol Nutr* 2021;72:833–41.
- 10 Rakha EA, Toss M, Shiino S, *et al.* Current and future applications of artificial intelligence in pathology: a clinical perspective. *J Clin Pathol* 2021;74:409–14.
- 11 Harrison JH, Gilbertson JR, Hanna MG, *et al.* Introduction to artificial intelligence and machine learning for pathology. *Arch Pathol Lab Med* 2021;145:1228–54.
- 12 Wei JW, Wei JW, Jackson CR, *et al.* Automated detection of celiac disease on duodenal biopsy slides: a deep learning approach. *J Pathol Inform* 2019;10:409–14.




- 13 Koh JEW, De Michele S, Sudarshan VK, *et al.* Automated interpretation of biopsy images for the detection of celiac disease using a machine learning approach. *Comput Methods Programs Biomed* 2021;203:106010.
- 14 Syed S, Al-Boni M, Khan MN, *et al.* Assessment of machine learning detection of environmental enteropathy and celiac disease in children. *JAMA Netw Open* 2019;2:e195822.
- 15 Sali R, Ehsan L, Kowsari K, *et al.* CeliacNet: celiac disease severity diagnosis on duodenal histopathological images using deep residual networks. *Proceedings (IEEE Int Conf Bioinformatics Biomed)* 2019;2019:962–67.
- 16 Najdawi F, Sucipto K, Mistry P, *et al.* Artificial intelligence enables quantitative assessment of ulcerative colitis histology. *Mod Pathol* 2023;36:100124.
- 17 Adelman DC, Murray J, Wu TT, *et al.* Measuring change in small intestinal histology in patients with celiac disease. *Am J Gastroenterol* 2018;113:339–47.
- 18 Bao F, Green PH, Bhagat G. An update on celiac disease histopathology and the road ahead. *Arch Pathol Lab Med* 2012;136:735–45.
- 19 Dickson BC, Streutker CJ, Chetty R. Coeliac disease: an update for pathologists. *J Clin Pathol* 2006;59:1008–16.
- 20 Moran CJ, Kolman OK, Russell GJ, *et al.* Neutrophilic infiltration in gluten-sensitive enteropathy is neither uncommon nor insignificant: assessment of duodenal biopsies from 267 pediatric and adult patients. *Am J Surg Pathol* 2012;36:1339–45.
- 21 Brown IS, Smith J, Rosty C. Gastrointestinal pathology in celiac disease: a case series of 150 consecutive newly diagnosed patients. *Am J Clin Pathol* 2012;138:42–9.

## FIGURE LEGENDS


- Figure 1** Proof-of-concept development of models based on HIFs on training data. CNN, convolutional neural network; H&E, haematoxylin and eosin; HIF, human interpretable feature; WSI, whole slide image.
- Figure 2** Overlays generated by cell segmentation model for model deployment.
- Figure 3** Tissue segmentation model showing distinct tissue regions. CD, celiac disease; ND, normal duodenum.
- Figure 4** Cell model confusion matrix showing sensitivity across different cell types.
- Figure 5** Accuracy of cell model predictions compared with pathologists. (A) Specificity comparison. (B) Sensitivity comparison.
- Figure 6** Example cell and tissue segmentation model correlation with modified Marsh score. (A) Surrogate features of villous blunting. (B) Surrogate features of crypt hyperplasia. (C) Surrogate features of intraepithelial lymphocyte infiltration.

### Step 1. Deployment

Deploy existing colon artifact, cell and goblet cell cytoplasm models



Artifact detection




Cell identification



### Step 2. Training and inference


Collect annotations of crypt epithelium, villous epithelium, lumen, lamina propria and muscularis mucosa to train an HIF-based tissue region model







### Step 3. Feature extraction

Develop read-outs to quantitate relevant histological features

Substance	Features
Neutrophils	Surface area of villous epithelium
Crypt epithelium	Surface area of crypt epithelium
Plasma cells	Count proportion of intraepithelial lymphocytes to enterocytes
Villous epithelium	
Intraepithelial lymphocytes	




- Goblet cell nuclei
- Enterocytes
- Intraepithelial lymphocytes
- Non-intraepithelial lymphocytes
- Plasma cells
- Eosinophils
- Neutrophils
- Other cells

**A****B****C****D**


Overlay showing ND (left)  
vs. CD (right) in:

- (A) Mucosa
- (B) All epithelium
- (C) Villous epithelium
- (D) Crypt epithelium

Ground truth



A



B

